Galecto develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation– for more information see: Products.
The company builds on more than 10 years of research for treatment of fibrosis and cancer, as well as the role of galectins, and the use of galectin modulators to treat disease. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is located in Copenhagen, Denmark.